Exclusive: Takeda to win EU approval for $62 billion Shire deal - sources

BRUSSELS (Reuters) - Japanese drugmaker Takeda Pharmaceutical is set to win conditional EU antitrust approval for its $62-billion (47.7 billion pounds) bid for London's Shire, the biggest ever overseas acquisition by a Japanese company, two people familiar with the matter said on Friday. Last month, Takeda offered to divest Shire Plc's pipeline compound SHP647 along with some associated rights after the European Commission voiced concerns about the overlap with its own drug for inflammatory..